company background image
IPN logo

Ipsen ENXTPA:IPN Stock Report

Last Price

€109.30

Market Cap

€9.0b

7D

-2.1%

1Y

-1.5%

Updated

21 Jul, 2024

Data

Company Financials +

IPN Stock Overview

Operates as a biopharmaceutical company worldwide.

IPN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends4/6

Ipsen S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ipsen
Historical stock prices
Current Share Price€109.30
52 Week High€130.70
52 Week Low€99.70
Beta0.62
11 Month Change-4.04%
3 Month Change-2.84%
1 Year Change-1.53%
33 Year Change25.75%
5 Year Change-0.64%
Change since IPO361.18%

Recent News & Updates

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Jun 16
An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

May 29
Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

May 22
We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Recent updates

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Jun 16
An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

May 29
Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

May 22
We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

May 08
Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Apr 20
Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Apr 13
There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Mar 26
Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

Dec 30
Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Dec 11
These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

Sep 28
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Sep 07
These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Jun 21
Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Jun 02
Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Ipsen's (EPA:IPN) Dividend Will Be €1.20

May 12
Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Mar 19
Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Mar 01
Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Jan 19
Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Dec 08
Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Nov 02
We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Oct 14
Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Aug 01
Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Jul 10
Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

May 26
Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

May 04
Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Apr 19
Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Is Ipsen (EPA:IPN) A Risky Investment?

Apr 18
Is Ipsen (EPA:IPN) A Risky Investment?

Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Mar 18
Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Shareholder Returns

IPNFR PharmaceuticalsFR Market
7D-2.1%-2.1%-2.8%
1Y-1.5%-6.0%-3.2%

Return vs Industry: IPN exceeded the French Pharmaceuticals industry which returned -6% over the past year.

Return vs Market: IPN exceeded the French Market which returned -3.2% over the past year.

Price Volatility

Is IPN's price volatile compared to industry and market?
IPN volatility
IPN Average Weekly Movement3.0%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement4.7%
10% most volatile stocks in FR Market9.7%
10% least volatile stocks in FR Market2.5%

Stable Share Price: IPN has not had significant price volatility in the past 3 months.

Volatility Over Time: IPN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19295,325David Loewwww.ipsen.com

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
IPN fundamental statistics
Market cap€9.03b
Earnings (TTM)€617.10m
Revenue (TTM)€3.31b

14.6x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPN income statement (TTM)
Revenue€3.31b
Cost of Revenue€571.20m
Gross Profit€2.74b
Other Expenses€2.12b
Earnings€617.10m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Jul 25, 2024

Earnings per share (EPS)7.47
Gross Margin82.72%
Net Profit Margin18.66%
Debt/Equity Ratio9.6%

How did IPN perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

16%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.